About Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals is a company based in Bridgewater (United States) founded in 2020 was acquired by Amneal in January 2021. Kashiv Specialty Pharmaceuticals offers products and services including Drug Delivery Technologies. Kashiv Specialty Pharmaceuticals operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Bridgewater, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Kashiv Specialty Pharmaceuticals, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals offers a comprehensive portfolio of products and services, including Drug Delivery Technologies.
Innovative solutions for effective and specialized drug delivery methods.
Funding Insights of Kashiv Specialty Pharmaceuticals
Detailed funding history for Kashiv Specialty Pharmaceuticals
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Amneal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of generics formulations
|
Locked | Locked | Locked |
Investor details for Kashiv Specialty Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kashiv Specialty Pharmaceuticals
Investment portfolio details for Kashiv Specialty Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kashiv Specialty Pharmaceuticals
Detailed financials for Kashiv Specialty Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kashiv Specialty Pharmaceuticals Comparisons
Peer comparison for Kashiv Specialty Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Kashiv Specialty Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kashiv Specialty Pharmaceuticals
Complete news archive for Kashiv Specialty Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals was founded in 2020.
Kashiv Specialty Pharmaceuticals is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Kashiv Specialty Pharmaceuticals was founded in 2020 and is based in Bridgewater, United States. Focus is placed on the pharmaceutical sector, where therapeutic solutions for rare diseases are developed. Operations include the advancement of drug candidate K127 for myasthenia gravis and skeletal muscle weakness. Additional candidates, such as K129 for ADHD, K128 for sialorrhea and movement disorders, and K114 for hypothyroidism, are created using proprietary drug delivery technology.
Kashiv Specialty Pharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Kashiv Specialty Pharmaceuticals offers Drug Delivery Technologies.
Kashiv Specialty Pharmaceuticals has 1 investor. Key investors include Amneal.